Similar articles

• Progress toward a practical BACE-1 inhibitor.

  Hills ID, Vacca JP. Hills ID, et al. Curr Opin Drug Discov Devel. 2007 Jul;10(4):383-91. Curr Opin Drug Discov Devel. 2007. PMID: 17659479 Review.
• Alzheimer's disease. A firm base for drug development.

  De Strooper B, König G. De Strooper B, et al. Nature. 1999 Dec 2;402(6761):471-2. doi: 10.1038/44973. Nature. 1999. PMID: 10591201 No abstract available.
• Progress toward the discovery and development of efficacious BACE inhibitors.

  Durham TB, Shepherd TA. Durham TB, et al. Curr Opin Drug Discov Devel. 2006 Nov;9(6):776-91. Curr Opin Drug Discov Devel. 2006. PMID: 17117686 Review.
• Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.

  Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB. Hussain I, et al. J Neurochem. 2007 Feb;100(3):802-9. doi: 10.1111/j.1471-4159.2006.04260.x. J Neurochem. 2007. PMID: 17156133
• Alzheimer's disease research: the future of BACE inhibitors.

  Burki T. Burki T. Lancet. 2018 Jun 23;391(10139):2486. doi: 10.1016/S0140-6736(18)31425-9. Lancet. 2018. PMID: 29976459 No abstract available.